International Assets Investment Management LLC Purchases Shares of 58,548 Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

International Assets Investment Management LLC purchased a new position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 58,548 shares of the specialty pharmaceutical company's stock, valued at approximately $7,201,000. International Assets Investment Management LLC owned 0.09% of Jazz Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently modified their holdings of the company. Los Angeles Capital Management LLC lifted its position in shares of Jazz Pharmaceuticals by 558.6% in the 3rd quarter. Los Angeles Capital Management LLC now owns 322,775 shares of the specialty pharmaceutical company's stock worth $41,780,000 after purchasing an additional 273,764 shares during the period. AQR Capital Management LLC increased its stake in Jazz Pharmaceuticals by 40.8% during the 3rd quarter. AQR Capital Management LLC now owns 179,111 shares of the specialty pharmaceutical company's stock valued at $23,184,000 after purchasing an additional 51,871 shares in the last quarter. Thompson Siegel & Walmsley LLC increased its stake in Jazz Pharmaceuticals by 242.8% during the 3rd quarter. Thompson Siegel & Walmsley LLC now owns 270,574 shares of the specialty pharmaceutical company's stock valued at $35,023,000 after purchasing an additional 191,648 shares in the last quarter. Hudson Bay Capital Management LP acquired a new position in Jazz Pharmaceuticals during the 3rd quarter valued at approximately $4,884,000. Finally, FMR LLC increased its stake in Jazz Pharmaceuticals by 8.1% during the 3rd quarter. FMR LLC now owns 1,333,129 shares of the specialty pharmaceutical company's stock valued at $172,560,000 after purchasing an additional 100,349 shares in the last quarter. Hedge funds and other institutional investors own 89.14% of the company's stock.

Jazz Pharmaceuticals Price Performance

Shares of NASDAQ JAZZ traded up $0.33 during trading on Monday, hitting $110.91. The company had a trading volume of 580,031 shares, compared to its average volume of 615,359. The stock has a fifty day simple moving average of $120.99 and a two-hundred day simple moving average of $122.95. Jazz Pharmaceuticals plc has a fifty-two week low of $110.08 and a fifty-two week high of $146.70. The firm has a market capitalization of $6.99 billion, a price-to-earnings ratio of 18.12, a price-to-earnings-growth ratio of 1.53 and a beta of 0.59. The company has a quick ratio of 1.85, a current ratio of 2.24 and a debt-to-equity ratio of 1.37.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last announced its earnings results on Wednesday, February 28th. The specialty pharmaceutical company reported $4.40 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.44 by ($0.04). The company had revenue of $1.01 billion during the quarter, compared to analyst estimates of $1.01 billion. Jazz Pharmaceuticals had a net margin of 10.82% and a return on equity of 31.27%. On average, research analysts expect that Jazz Pharmaceuticals plc will post 16.24 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the stock. Barclays cut their price objective on shares of Jazz Pharmaceuticals from $235.00 to $230.00 and set an "overweight" rating on the stock in a research note on Friday, March 1st. HC Wainwright cut their price objective on shares of Jazz Pharmaceuticals from $204.00 to $200.00 and set a "buy" rating on the stock in a research note on Thursday, March 14th. Needham & Company LLC reiterated a "buy" rating and issued a $220.00 price objective on shares of Jazz Pharmaceuticals in a research note on Wednesday, March 20th. Stifel Nicolaus increased their price target on shares of Jazz Pharmaceuticals from $225.00 to $230.00 and gave the stock a "buy" rating in a report on Friday, March 15th. Finally, Royal Bank of Canada reissued an "outperform" rating and set a $195.00 price target on shares of Jazz Pharmaceuticals in a report on Thursday, February 29th. Two equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $195.08.

Insider Transactions at Jazz Pharmaceuticals

In related news, CAO Patricia Carr sold 1,936 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Wednesday, March 6th. The shares were sold at an average price of $119.64, for a total value of $231,623.04. Following the completion of the transaction, the chief accounting officer now owns 8,364 shares in the company, valued at $1,000,668.96. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other Jazz Pharmaceuticals news, CFO Philip L. Johnson acquired 12,000 shares of the company's stock in a transaction that occurred on Friday, March 1st. The stock was purchased at an average price of $119.65 per share, for a total transaction of $1,435,800.00. Following the completion of the acquisition, the chief financial officer now owns 27,932 shares of the company's stock, valued at approximately $3,342,063.80. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CAO Patricia Carr sold 1,936 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Wednesday, March 6th. The shares were sold at an average price of $119.64, for a total transaction of $231,623.04. Following the completion of the transaction, the chief accounting officer now owns 8,364 shares of the company's stock, valued at approximately $1,000,668.96. The disclosure for this sale can be found here. Insiders own 4.40% of the company's stock.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.